Cytosorbents - רווח החברה לפני מסים, ריבית ופחת CTSO

Unstable cash flow resulting from technology implementation costs and R&D currently drives the dynamics of Cytosorbents (CTSO). Absolute EBITDA illustrates the market reaction, where 0.00 expresses the latest level of the metric. Cytosorbents generates revenue from the sale of blood purification cartridges, while the defensive status of the business completely eliminates the impact of macroeconomic downturns on operating results.

The monopoly position of Cytosorbents in the cytokine sorption niche and the sale of patented cartridges generate a stable cash flow, which reflects the current EBITDA value of 0.00. This metric measures operating efficiency excluding depreciation and taxes, allowing investors to assess the company's actual ability to service obligations using liquid cash from its core business activities.